From Nusinersen to Inclisiran, oligonucleotide APIs are rapidly reshaping modern drug development. Explore the role of oligonucleotide CDMOs in enabling analytical innovation and scalable, compliant manufacturing across the RNA therapeutic frontier.
In today’s biotech landscape, quality is essential. For therapeutics based on peptides or oligonucleotides, many of which treat complex or life-threatening conditions, GMP compliance is a foundational element of regulatory approval and patient trust.
Gain insights from Joseph Denby's rapid-fire Q&A spotlight at NextGen Biomed, where he explores the landscape of peptide and oligo APIs, as well as the role of green chemistry in manufacturing.
